STOCK TITAN

American Oncology Network Expands Radiology and Imaging Program with New Physician Leaders and Advances Radiopharmaceutical Therapies

(Very Positive)
Tags

American Oncology Network (NASDAQ:AONC) announced the continued expansion of its radiology, imaging and radiopharmaceutical therapy (RPT) program, emphasizing growth in radioligand therapy centers and new physician leadership. Since launching its first radioligand therapy site in 2023 at Genesis Cancer & Blood Institute in Hot Springs, Arkansas, the network has grown to nine active radioligand therapy centers across Arizona, Florida, Arkansas, North Carolina, Texas and Ohio, with five additional sites under development.

According to the company, AON supports partner practices with patient population assessments, facility planning, regulatory guidance, physician training, staffing and ongoing operational oversight. AON added two key physician leaders: Robert J. McDonald, MD, FACNM, as radiology medical director and in-house reading radiologist, and Jason Berilgen, MD, as medical director of radiation oncology. They are tasked with overseeing radiology and radiation oncology services, protocol development, radiotheranostics and evidence-based treatment expansion across the network, reinforcing AON’s focus on bringing advanced cancer care into community settings.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.

Market Context

AONC's historical record includes a -99.17% reaction and a 16.13% reaction to prior announcements. T...
Analysis

AONC's historical record includes a -99.17% reaction and a 16.13% reaction to prior announcements. That range adds context to this program expansion, with execution across planned sites a relevant risk to monitor.

Key Figures

Radioligand therapy centers: 9 active centers Sites under development: 5 additional sites Program launch: 2023 +2 more
5 metrics
Radioligand therapy centers 9 active centers Current AON network
Sites under development 5 additional sites Radiopharmaceutical therapy network
Program launch 2023 First radioligand therapy site
Physician appointments 2 key appointments Radiology and radiation oncology leadership
Clinical experience More than 30 years Robert J. McDonald, MD, FACNM

Historical Context

5 past events · Latest: Jun 09 (Positive)
Pattern 5 events
Date Event Sentiment 24h Move Catalyst
Jun 09 physician appointment Positive -99.2% Partner practice added a board-certified medical oncologist and hematologist to its physician team.
May 21 care-network affiliation Positive +0.0% Zangmeister joined Ohio State's James Cancer Network, expanding access to advanced therapies.
Apr 30 physician appointment Positive +2.8% MidAmerica Cancer Care added a board-certified medical oncologist and hematologist in Kansas City.
Apr 22 conference participation Positive +16.1% AON announced participation in 11 sessions at the Community Oncology Alliance annual conference.
Mar 05 network partnership Positive -7.3% Oncology Consultants joined AON, adding South Texas locations and clinical resources.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Positive operational and access announcements produced mixed historical reactions, including both gains and declines.

Key Terms

radiopharmaceutical therapies, radioligand therapy, radiotheranostic therapies, image-guided radiation therapy, +1 more
5 terms
radiopharmaceutical therapies medical
"support for radiopharmaceutical therapies, one of the fastest-growing areas"
Therapies that pair a radioactive isotope with a drug or molecule that seeks out diseased tissue, delivering radiation directly to cancerous or other abnormal cells much like a guided missile targeting a specific site. They matter to investors because their clinical trial progress, regulatory approvals, manufacturing complexity, distribution needs, and reimbursement rules strongly affect company value and market opportunity, and small changes in evidence or regulation can change commercial prospects quickly.
radioligand therapy medical
"AON’s radioligand therapy program has expanded significantly"
A treatment that uses a small molecule or antibody designed to seek out specific cells and deliver a tiny dose of radiation directly to them, like a guided missile carrying a limited explosive to a particular target rather than carpeting an area. Investors care because successful radioligand therapies can become high-value prescription products with clear market niches, regulatory hurdles, and reimbursement decisions that strongly affect a developer’s revenue and risk profile.
radiotheranostic therapies medical
"performs advanced radiotheranostic therapies"
A class of medical treatments that combine a diagnostic scan and a targeted therapy using the same or similar radioactive molecules: one function helps find and visualize disease inside the body, and the other delivers radiation to kill or control the disease. Think of it like a guided missile system where the radioactive tracer first pinpoints the target and the therapeutic version then strikes it; this matters to investors because development, regulatory approval, manufacturing capacity, patent position, and payer reimbursement determine commercial value and risk.
image-guided radiation therapy medical
"expertise in image-guided radiation therapy"
Image-guided radiation therapy is a cancer treatment approach that uses real-time medical images (like CT, MRI, or X-ray) to steer and adjust radiation beams so they hit tumors more precisely, similar to using GPS to guide a delivery to a moving address. It matters to investors because the technology affects demand for specialized equipment and software, influences treatment costs, hospital capital spending, reimbursement and regulatory decisions, and can change clinical outcomes and procedure volumes in oncology care.
stereotactic body radiotherapy medical
"stereotactic body radiotherapy, stereotactic radiosurgery"
A targeted radiation treatment that delivers very high doses of radiation to a small tumor area in the body with sub-millimeter precision, often over one to five sessions. Think of it as a precision knife that focuses energy on a single spot while sparing nearby healthy tissue. It matters to investors because its use, clinical results, regulatory approvals, and related equipment or software sales can influence healthcare company revenues and market value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

FORT MYERS, Fla., July 23, 2026 (GLOBE NEWSWIRE) -- American Oncology Network (AON), one of the nation’s fastest-growing networks of community oncology practices, continues to strengthen its radiology, imaging and radiopharmaceutical therapy (RPT) program through strategic physician leadership, expanded clinical capabilities and ongoing investment in innovative cancer care that brings advanced treatments closer to where patients live and work.

14083_AON_Radiology-Round-Up_Press-Release_Headshot_260721_FINAL (2)

This year, AON has accelerated the growth of its radiology and radiation oncology services while expanding support for radiopharmaceutical therapies, one of the fastest-growing areas in cancer treatment. Through clinical expertise, physician education and operational support, AON is helping its partner practices prepare for the next generation of targeted cancer therapies.

AON’s radioligand therapy program has expanded significantly since launching its first site at AON partner practice, Genesis Cancer & Blood Institute in Hot Springs, Arkansas, in 2023. The network now has nine active radioligand therapy centers, including:

Five additional sites are currently under development, reflecting AON’s long-term commitment to expanding patient access to advanced radiopharmaceutical therapies in community oncology settings nationwide.

“Radiopharmaceutical therapies continue to transform oncology, and AON is committed to ensuring patients can access these innovative treatments in their own communities,” said Todd Schonherz, AON chief executive officer. “The continued growth of our radioligand therapy program, combined with investments in physician leadership and clinical infrastructure, further positions our network to expand the delivery of innovative, world-class cancer care in communities across the country.”

AON provides partner practices that open radioligand therapy centers comprehensive support for program development, including patient population assessments, facility planning, regulatory guidance, physician training, staffing resources and ongoing operational oversight.

“Radiopharmaceutical therapies represent one of the most exciting advances in oncology, and community practices have an opportunity to prepare today for what’s next,” said Guy Messer, AON vice president of radiation and radiology services. “Since launching our first radioligand therapy program in 2023, we’ve continued to expand access across the AON network while helping practices build sustainable programs that are ready to deliver both today’s therapies and tomorrow’s innovations.”

New Physician Leadership

As part of this continued growth, AON recently expanded its physician leadership team with two key appointments.

Robert J. McDonald, MD, FACNM, joined AON as radiology medical director and in-house reading radiologist. A nationally recognized, board-certified nuclear medicine physician with more than 30 years of experience, Dr. McDonald oversees radiology services, provides PET and CT interpretation for multiple AON partner practices, performs advanced radiotheranostic therapies, and chairs the radiology segment of the Physician Leadership Committee. He also leads physician preceptorships, supports protocol development and helps expand radioligand therapy capabilities across the network.

“AON has created an environment where radiology, nuclear medicine and oncology teams can work together to bring advanced imaging and radiopharmaceutical therapies directly into community practice settings,” Dr. McDonald said. “I’m excited to help continue to expand these capabilities so more patients can benefit from highly specialized care close to home.”

Jason Berilgen, MD was named medical director of radiation oncology. In this role, he provides clinical leadership for AON’s radiation oncology initiatives, oversees the development of clinical protocols, supports the expansion of evidence-based therapies and chairs both the AON Radiation Oncology Committee and the radiation oncology segment of the Physician Leadership Committee. Dr. Berilgen is a board-certified radiation oncologist with extensive expertise in image-guided radiation therapy, stereotactic body radiotherapy, stereotactic radiosurgery and other advanced treatment techniques.

“Radiation oncology continues to evolve rapidly, and collaboration across specialties is essential to delivering the best possible outcomes for patients,” Dr. Berilgen said. “I look forward to continuing to work with physicians across the AON network to strengthen clinical programs, expand access to evidence-based treatments and support innovation in community oncology care.”

Together, these physician appointments and the continued expansion of AON’s therapeutic radioligand network reflect AON’s ongoing commitment to ensuring cancer patients have access to innovative, high-quality cancer care in the communities where they live and work.

About American Oncology Network
American Oncology Network (AON) is an alliance of physicians and seasoned healthcare leaders partnering to ensure the long-term success and viability of community oncology and other specialties. Founded in 2018, AON’s rapidly expanding network represents more than 350 providers practicing across 21 states. AON pioneers innovative healthcare solutions through its physician-led model, fostering value-based care that improves patient outcomes while reducing costs and expanding access to quality care. AON equips its network physicians with the tools they need to thrive independently while providing comprehensive support, integrated revenue-diversifying ancillary services, and practice management expertise, enabling physicians to focus on what matters most – providing the highest standard of care for every patient. AON is committed to promoting health equity by addressing disparities in cancer care and ensuring that all patients have access to the care they need to achieve optimal health outcomes. With a focus on innovation and collaboration, AON is shaping the future of community oncology. For more information, please visit AONcology.com or follow us on LinkedIn, Facebook, X (formerly Twitter) and YouTube.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d2adaa7d-a57b-4fcf-8f2b-dfffe0a6ac76



Media Contact:
Karen Riley Sawyer
American Oncology Network
Karen.Sawyer@AONcology.com

FAQ

How is American Oncology Network (AONC) expanding its radiopharmaceutical therapy program in 2026?

American Oncology Network is expanding its radiopharmaceutical therapy program by operating nine radioligand therapy centers with five additional sites under development. According to the company, this growth aims to increase patient access to advanced radiopharmaceutical treatments in community oncology settings nationwide.

How many radioligand therapy centers does American Oncology Network (AONC) currently operate?

American Oncology Network currently operates nine active radioligand therapy centers across multiple states. According to the company, these include locations in Arizona, Florida, Arkansas, North Carolina, Texas and Ohio, with more sites being developed to broaden community access.

Who is leading radiology services at American Oncology Network (AONC) in 2026?

Robert J. McDonald, MD, FACNM serves as radiology medical director at American Oncology Network. According to the company, he oversees radiology services, provides PET and CT interpretations, performs advanced radiotheranostic therapies and guides radioligand therapy expansion and physician education across the network.

Who is the medical director of radiation oncology at American Oncology Network (AONC)?

Jason Berilgen, MD is the medical director of radiation oncology at American Oncology Network. According to the company, he leads radiation oncology initiatives, develops clinical protocols, supports evidence-based therapies and chairs AON’s Radiation Oncology Committee and related Physician Leadership Committee segment.

What support does American Oncology Network (AONC) provide to practices opening radioligand therapy centers?

American Oncology Network provides comprehensive support including patient population assessments, facility planning and regulatory guidance. According to the company, it also offers physician training, staffing resources and ongoing operational oversight to help partner practices build sustainable radioligand therapy programs.

Which community oncology practices are part of American Oncology Network’s radioligand therapy sites?

American Oncology Network’s radioligand therapy sites include partners such as Genesis Cancer & Blood Institute and practices in Arizona, Florida, North Carolina, Texas and Ohio. According to the company, these community-based centers deliver advanced radiopharmaceutical therapies closer to where patients live and work.

What is the goal of American Oncology Network’s investment in radiology and imaging for AONC patients?

The goal is to bring advanced imaging, radiology and radiopharmaceutical therapies into community oncology settings. According to the company, investments in physician leadership, infrastructure and protocols aim to expand access to innovative, evidence-based cancer care for patients near their homes.